TREMFYATM is a human monoclonal IgG1λ antibody that selectively binds to the p19 subunit of IL-23 and inhibits its interaction with the IL-23 receptor.
IL-23 is a naturally occurring cytokine that is involved in normal inflammatory and immune responses1
Interaction between IL-23 and its receptor drives the differentiation, proliferation, and survival of Th17 cells, which produce inflammatory cytokines5-7
By blocking IL-23, TREMFYATM inhibits the release of important pro-inflammatory cytokines
Serum levels of IL-17A, IL-17F, and IL-22 were reduced relative to pretreatment levels based on an exploratory analysis
The clinical significance of these findings is not known
The mean half-life of guselkumab in patients with plaque psoriasis: ≈15 to 18 days1